Lantheus Holdings, Inc. (LNTH) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
How it makes money
It generates revenue selling PYLARIFY through a network of cyclotrons that must deliver the 110-minute half-life F-18 imaging agent to hospitals daily.
Profits are primarily driven by the Radiopharmaceutical Oncology segment, specifically PYLARIFY, a PSMA PET imaging agent for prostate cancer. Because the F-18 isotope decays rapidly, the company cannot use a traditional centralized supply chain.
Instead, it utilizes an assembled network of manufacturing facilities containing cyclotrons to produce and distribute the agent for immediate clinical use. Earnings depend on the ability of these facilities to manufacture and deliver the product at specific times preferred by healthcare providers.
What protects it: the moat
It maintains position through an established network of PET manufacturing facilities, where each site requires individual FDA approval to produce the short-lived isotopes.
The company protects its earnings through the high barrier to entry created by its nationwide manufacturing network. Unlike standard drugs, each individual site in the network is deemed a separate manufacturing location by the FDA and must undergo its own approval process.
This regulatory requirement makes it difficult for competitors to rapidly scale a rival imaging agent, as they must replicate the site-by-site qualification and technology transfer process that the company has already completed.
What growth costs
It spent $352.9 million upfront in cash for the LMI Acquisition and $35.0 million for the RM2 Asset Purchase.
The company reinvests heavily in strategic acquisitions to expand its oncology and neurology diagnostic portfolios. In 2025, it acquired Life Molecular Imaging to obtain Neuraceq, an Alzheimer’s diagnostic, and its associated international commercial infrastructure.
Additionally, it acquired rights to the RM2 radiotherapeutic and radiodiagnostic pair to bolster its clinical pipeline. Future growth also relies on the successful development and regulatory approval of new kits like LNTH-2501 and MK-6240.
What could damage it
Earnings could be impaired if Medicare reimbursement for PYLARIFY based on mean unit cost fails to cover hospital expenses after transitional pass-through status expires.
Profits are highly sensitive to government reimbursement models. Following the expiration of transitional pass-through status (TPT), Medicare moved PYLARIFY to an unbundled payment model based on mean unit cost (MUC), which is lower than the previous average sales price.
If these separate payments do not adequately cover the total costs for hospitals performing the procedures, clinicians may switch to newer competitive products that still benefit from higher-margin TPT status, eroding the company's oncology market share.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.